The Biggest Real-World Psychedelic Study Ever Is Now Live

The Biggest Real-World Psychedelic Study Ever Is Now Live  Most psychedelic research happens in carefully controlled conditions. Typically a screened population, in a clinical setting, with standardised doses. This model has given us some of the most compelling mental health data in decades, but it has also, inevitably, told only part of the story.So UCSF’s Carhart-Harris Lab is now investigating the other side of the story – people taking psychedelics outside the lab.The CANOPY Project (Cohort Study Assessing Naturalistic Outcomes of Psychedelic Use) is a large-scale, real-world survey initiative designed to follow people

Why real-world data matters

Clinical trials are built on constraints. You recruit a homogeneous population, standardise the conditions, and control for everything you can. That’s how you establish efficacy. But it also means the findings come from a narrow slice of humanity, often middle-aged, often white, often carrying a https://mushies.co.uk/ specific diagnosis like treatment-resistant depression. What about everyone else?The CANOPY team’s interest in broadening this lens was sharpened by an accidental finding in a previous naturalistic dataset. A colleague at Imperial College London analysed the data and found a significant proportion of participants had reported some form of eating disorder. No clinical trial had ever included this population. There were no measures specific to eating disorder symptoms. CANOPY is designed to fix exactly that.

The sub-studies: from brain scans to ibogaine

CANOPY functions as an umbrella structure with several active branches underneath. The most developed is BABS (Bay Area Brains). This sub-study is currently live and recruiting people who are planning to take psilocybin for the very first time